Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517486 | 0.92 | SIGMAR1 (0.68) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL17792376 | 0.89 | ACHE (0.64) | SIGMAR1KDM4EHTR2AHTR2C | |
| SCHEMBL10397222 | 0.88 | SIGMAR1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL29411058 | 0.87 | SIGMAR1 (0.75) | SIGMAR1HTR1AGRIN2B | |
| Hydrochloric Acid SCHEMBL16335548 | 0.86 | SIGMAR1 (0.73) | SIGMAR1HTR1AGRIN2B | |
| Hydrochloric Acid SCHEMBL16335321 | 0.86 | SIGMAR1 (0.73) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL7783645 | 0.81 | DRD1 (0.62) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL6369610 | 0.80 | HTR1A (0.71) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10396301 | 0.80 | DRD1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL1415530 | 0.78 | HTR1A (0.81) | SIGMAR1HTR1AKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | SIGMAR1 923/4885HTR1A 161/4885KDM4E 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.